Detail of "7075-11-8"

Reference

Antitumor activity of 1-b-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative

Antitumor activity of 1-b-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative. Kato, Yoshinori; Saito, Masahiko; Fukushima, Hisashi; Takeda, Yumiko; Hara, Takeshi (Dep. Med. Chem. Biochem., Teijin Inst. Biomed. Res., Tokyo 191, Japan). Cancer Res., 44(1), 25-30 (English) 1984. CODEN: CNREA8. ISSN: 0008-5472. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 33, 34 Four types of ara-C conjugates with poly-L-glutamic acid(PLGA) or poly-N5-(2-hydroxyethyl)-L-glutamine (PHEG) were prepd. The conjugates were made by linking ara-C [147-94-4] to the carboxyl groups of PLGA directly at N-4 of ara-C or indirectly through the 2-aminoethylphosphoryl or 6-aminohexylphosphoryl side chain which had been introduced to C-5' of ara-C, or made by converting the remaining carboxyl groups in the PLGA conjugates to the 2-hydroxyethylamide groups. Studies in vitro showed that the conjugates had decreased cytotoxicity against L1210 cells when compared with that of ara-C. Studies in vivo showed that all of the conjugates, except ara-CMP(C2):PLGA, had a greater antitumor activity than did ara-C in L1210 tumor-bearing mice which were treated by a single i.p.In this article, certain chemicals are used. Some of their cas registry numbers are 89203-20-3 and 27878-59-7 injection of either the conjugates or the control ara-C on day 1. The largest antitumor activity [increased life span (ILS) 170%] was obsd. with a dosage of 50 mg (equiv. ara-C/kg) of ara-C:PHEG. When mice which had been inoculated i.p. with 1 ′ 105 L1210 cells were treated with an i.p. injection of 12.5 or 25 mg (equiv. ara-C/kg) of ara-C:PHEG daily for 5 days starting from day 1, 2 of 5 mice survived more than 42 days, and the ILS of the remaining mice was 153 and 184%. The injections of 3.2 mg (equiv. ara-C/kg) of ara-C:PHEG showed a moderate antitumor activity with an ILS of 113% which was similar to the ILS (119%) found when unconjugated ara-C (400 mg/kg) was used to treat tumor-bearing mice. In in vitro release expts., ara-C was released slowly from ara-C:PLGA at pH 7.4, and ara-CMP(C2):PLGA was chem. stable but cleaved by phosphodiesterase, acid phosphatase, and alk. phosphatase to give mainly 1-b-D-arabinofuranosylcytosine 5'-monophosphate [7075-11-8]. .

Synthesis and biologic studies of arabinosylcytosine 5'-methylphosphonate

Synthesis and biologic studies of arabinosylcytosine 5'-methylphosphonate. Gormley, Paul E.; Benvenuto, John; Cysyk, Richard L. (Natl. Cancer Inst., Natl. Inst. Health, Bethesda, Md., USA). Biochem. Pharmacol., 26(14), 1291-4 (English) 1977. CODEN: BCPCA6. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) Section cross-reference(s): 33 Arabinosylcytosine-5'-methylphosphonate (I) [53220-20-5] was synthesized as an analog of arabinosylcytosine monophosphate (II) [7075-11-8] that would be membrane permeable and resistant to serum phosphatase attack and to nucleoside deaminase inactivation. II was inhibitory to leukemia P388 in vitro but required concns. 90-fold greater than that of arabinosylcytosine for comparable cell inhibition. Both I and II were competitive inhibitors of dCMP kinase [37278-21-0] from leukemia L1210 with Ki of 4.0 .times. 10-3 and 4.4 .times. 10-3M resp. However, II was a substrate for dCMP kinase but I was not, which precludes the usefulness of I as a functional analog of II.